Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer

Michael R. McDevitt; Daniel L.J. Thorek; Takeshi Hashimoto; Tatsuo Gondo; Darren R. Veach; Sai Kiran Sharma; Teja Muralidhar Kalidindi; Diane S. Abou; Philip A. Watson; Bradley J. Beattie; Oskar Vilhemsson Timmermand; Sven Erik Strand; Jason S. Lewis; Peter T. Scardino; Howard I. Scher; Hans Lilja; Steven M. Larson; David Ulmert

doi:10.1038/s41467-018-04107-w

Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer

Michael R. McDevitt, Daniel L.J. Thorek, Takeshi Hashimoto, Tatsuo Gondo, Darren R. Veach, Sai Kiran Sharma, Teja Muralidhar Kalidindi, Diane S. Abou, Philip A. Watson, Bradley J. Beattie, Oskar Vilhemsson Timmermand, Sven Erik Strand, Jason S. Lewis, Peter T. Scardino, Howard I. Scher, Hans Lilja, Steven M. Larson, David Ulmert

School of Medicine

Research output: Contribution to journal › Article

Abstract

Human kallikrein peptidase 2 (hK2) is a prostate specific enzyme whose expression is governed by the androgen receptor (AR). AR is the central oncogenic driver of prostate cancer (PCa) and is also a key regulator of DNA repair in cancer. We report an innovative therapeutic strategy that exploits the hormone-DNA repair circuit to enable molecularly-specific alpha particle irradiation of PCa. Alpha-particle irradiation of PCa is prompted by molecularly specific-targeting and internalization of the humanized monoclonal antibody hu11B6 targeting hK2 and further accelerated by inherent DNA-repair that up-regulate hK2 (KLK2) expression in vivo. hu11B6 demonstrates exquisite targeting specificity for KLK2. A single administration of actinium-225 labeled hu11B6 eradicates disease and significantly prolongs survival in animal models. DNA damage arising from alpha particle irradiation induces AR and subsequently KLK2, generating a unique feed-forward mechanism, which increases binding of hu11B6. Imaging data in nonhuman primates support the possibility of utilizing hu11B6 in man.

Original language	English (US)
Article number	1629
Journal	Nature communications
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41467-018-04107-w
State	Published - Dec 1 2018

ASJC Scopus subject areas

Chemistry(all)
Biochemistry, Genetics and Molecular Biology(all)
Physics and Astronomy(all)

Access to Document

10.1038/s41467-018-04107-w

Fingerprint Dive into the research topics of 'Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer'. Together they form a unique fingerprint.

Cite this

McDevitt, M. R., Thorek, D. L. J., Hashimoto, T., Gondo, T., Veach, D. R., Sharma, S. K., Kalidindi, T. M., Abou, D. S., Watson, P. A., Beattie, B. J., Timmermand, O. V., Strand, S. E., Lewis, J. S., Scardino, P. T., Scher, H. I., Lilja, H., Larson, S. M., & Ulmert, D. (2018). Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nature communications, 9(1), [1629]. https://doi.org/10.1038/s41467-018-04107-w

Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. / McDevitt, Michael R.; Thorek, Daniel L.J.; Hashimoto, Takeshi; Gondo, Tatsuo; Veach, Darren R.; Sharma, Sai Kiran; Kalidindi, Teja Muralidhar; Abou, Diane S.; Watson, Philip A.; Beattie, Bradley J.; Timmermand, Oskar Vilhemsson; Strand, Sven Erik; Lewis, Jason S.; Scardino, Peter T.; Scher, Howard I.; Lilja, Hans; Larson, Steven M.; Ulmert, David.

In: Nature communications, Vol. 9, No. 1, 1629, 01.12.2018.

Research output: Contribution to journal › Article

McDevitt, MR, Thorek, DLJ, Hashimoto, T, Gondo, T, Veach, DR, Sharma, SK, Kalidindi, TM, Abou, DS, Watson, PA, Beattie, BJ, Timmermand, OV, Strand, SE, Lewis, JS, Scardino, PT, Scher, HI, Lilja, H, Larson, SM & Ulmert, D 2018, 'Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer', Nature communications, vol. 9, no. 1, 1629. https://doi.org/10.1038/s41467-018-04107-w

McDevitt, Michael R. ; Thorek, Daniel L.J. ; Hashimoto, Takeshi ; Gondo, Tatsuo ; Veach, Darren R. ; Sharma, Sai Kiran ; Kalidindi, Teja Muralidhar ; Abou, Diane S. ; Watson, Philip A. ; Beattie, Bradley J. ; Timmermand, Oskar Vilhemsson ; Strand, Sven Erik ; Lewis, Jason S. ; Scardino, Peter T. ; Scher, Howard I. ; Lilja, Hans ; Larson, Steven M. ; Ulmert, David. / Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. In: Nature communications. 2018 ; Vol. 9, No. 1.

@article{9665438b4e524b6f8d9ea6283a99ede5,

title = "Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer",

abstract = "Human kallikrein peptidase 2 (hK2) is a prostate specific enzyme whose expression is governed by the androgen receptor (AR). AR is the central oncogenic driver of prostate cancer (PCa) and is also a key regulator of DNA repair in cancer. We report an innovative therapeutic strategy that exploits the hormone-DNA repair circuit to enable molecularly-specific alpha particle irradiation of PCa. Alpha-particle irradiation of PCa is prompted by molecularly specific-targeting and internalization of the humanized monoclonal antibody hu11B6 targeting hK2 and further accelerated by inherent DNA-repair that up-regulate hK2 (KLK2) expression in vivo. hu11B6 demonstrates exquisite targeting specificity for KLK2. A single administration of actinium-225 labeled hu11B6 eradicates disease and significantly prolongs survival in animal models. DNA damage arising from alpha particle irradiation induces AR and subsequently KLK2, generating a unique feed-forward mechanism, which increases binding of hu11B6. Imaging data in nonhuman primates support the possibility of utilizing hu11B6 in man.",

author = "McDevitt, {Michael R.} and Thorek, {Daniel L.J.} and Takeshi Hashimoto and Tatsuo Gondo and Veach, {Darren R.} and Sharma, {Sai Kiran} and Kalidindi, {Teja Muralidhar} and Abou, {Diane S.} and Watson, {Philip A.} and Beattie, {Bradley J.} and Timmermand, {Oskar Vilhemsson} and Strand, {Sven Erik} and Lewis, {Jason S.} and Scardino, {Peter T.} and Scher, {Howard I.} and Hans Lilja and Larson, {Steven M.} and David Ulmert",

year = "2018",

month = dec,

day = "1",

doi = "10.1038/s41467-018-04107-w",

language = "English (US)",

volume = "9",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer

AU - McDevitt, Michael R.

AU - Thorek, Daniel L.J.

AU - Hashimoto, Takeshi

AU - Gondo, Tatsuo

AU - Veach, Darren R.

AU - Sharma, Sai Kiran

AU - Kalidindi, Teja Muralidhar

AU - Abou, Diane S.

AU - Watson, Philip A.

AU - Beattie, Bradley J.

AU - Timmermand, Oskar Vilhemsson

AU - Strand, Sven Erik

AU - Lewis, Jason S.

AU - Scardino, Peter T.

AU - Scher, Howard I.

AU - Lilja, Hans

AU - Larson, Steven M.

AU - Ulmert, David

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Human kallikrein peptidase 2 (hK2) is a prostate specific enzyme whose expression is governed by the androgen receptor (AR). AR is the central oncogenic driver of prostate cancer (PCa) and is also a key regulator of DNA repair in cancer. We report an innovative therapeutic strategy that exploits the hormone-DNA repair circuit to enable molecularly-specific alpha particle irradiation of PCa. Alpha-particle irradiation of PCa is prompted by molecularly specific-targeting and internalization of the humanized monoclonal antibody hu11B6 targeting hK2 and further accelerated by inherent DNA-repair that up-regulate hK2 (KLK2) expression in vivo. hu11B6 demonstrates exquisite targeting specificity for KLK2. A single administration of actinium-225 labeled hu11B6 eradicates disease and significantly prolongs survival in animal models. DNA damage arising from alpha particle irradiation induces AR and subsequently KLK2, generating a unique feed-forward mechanism, which increases binding of hu11B6. Imaging data in nonhuman primates support the possibility of utilizing hu11B6 in man.

AB - Human kallikrein peptidase 2 (hK2) is a prostate specific enzyme whose expression is governed by the androgen receptor (AR). AR is the central oncogenic driver of prostate cancer (PCa) and is also a key regulator of DNA repair in cancer. We report an innovative therapeutic strategy that exploits the hormone-DNA repair circuit to enable molecularly-specific alpha particle irradiation of PCa. Alpha-particle irradiation of PCa is prompted by molecularly specific-targeting and internalization of the humanized monoclonal antibody hu11B6 targeting hK2 and further accelerated by inherent DNA-repair that up-regulate hK2 (KLK2) expression in vivo. hu11B6 demonstrates exquisite targeting specificity for KLK2. A single administration of actinium-225 labeled hu11B6 eradicates disease and significantly prolongs survival in animal models. DNA damage arising from alpha particle irradiation induces AR and subsequently KLK2, generating a unique feed-forward mechanism, which increases binding of hu11B6. Imaging data in nonhuman primates support the possibility of utilizing hu11B6 in man.

UR - http://www.scopus.com/inward/record.url?scp=85045977181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045977181&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-04107-w

DO - 10.1038/s41467-018-04107-w

M3 - Article

C2 - 29691406

AN - SCOPUS:85045977181

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 1629

ER -